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Abstract
Purpose: An open-label phase I/II study of single-agent obatoclax determined a maximum tolerated dose (MTD) and
schedule, safety, and efficacy in older patients ($70 yr) with untreated acute myeloid leukemia (AML).
Experimental Design: Phase I evaluated the safety of obatoclax infused for 3 hours on 3 consecutive days (3 h63 d) in 2-
week cycles. Initial obatoclax dose was 30 mg/day (3 h63 d; n = 3). Obatoclax was increased to 45 mg/day (3 h63 d) if #1
patient had a dose-limiting toxicity (DLT) and decreased to 20 mg/day (3 h63 d) if DLT occurred in $2 patients. In the
phase II study, 12 patients were randomized to receive obatoclax at the dose identified during phase I (3 h63 d) or 60 mg/
day administered by continuous infusion over 24 hours for 3 days (24 h63 d) to determine the morphologic complete
response rate.
Results: In phase I, two of three patients receiving obatoclax 30 mg/day (3 h63 d) experienced grade 3 neurologic DLTs
(confusion, ataxia, and somnolence). Obatoclax was decreased to 20 mg/day (3 h63 d). In phase II, no clinically relevant
safety differences were observed between the 20 mg/day (3 h63 d; n = 7) and 60 mg/day (24 h63 d; n = 5) arms.
Neurologic and psychiatric adverse events were most common and were generally transient and reversible. Complete
response was not achieved in any patient.
Conclusions: Obatoclax 20 mg/day was the MTD (3 h63 d) in older patients with AML. In the schedules tested, single-agent
obatoclax was not associated with an objective response. Evaluation in additional subgroups or in combination with other
chemotherapy modalities may be considered for future study.
Trial Registration: ClinicalTrials.gov NCT00684918
Citation: Schimmer AD, Raza A, Carter TH, Claxton D, Erba H, et al. (2014) A Multicenter Phase I/II Study of Obatoclax Mesylate Administered as a 3- or 24-Hour
Infusion in Older Patients with Previously Untreated Acute Myeloid Leukemia. PLoS ONE 9(10): e108694. doi:10.1371/journal.pone.0108694
Editor: Maria R. Baer, University of Maryland, United States of America
Received May 16, 2014; Accepted August 19, 2014; Published October 6, 2014
Copyright:  2014 Schimmer et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All data are included within the paper.
Funding: The study that is the subject of this manuscript was sponsored by Gemin X Pharmaceuticals, Inc., which was acquired by Cephalon, Inc., a wholly-
owned subsidiary of Teva Pharmaceutical Industries, Ltd (TEVA). The development and publication of this manuscript has been financially supported by TEVA.
Employees of TEVA were actively involved in the development of the manuscript, including providing data as well as review and comment of manuscript drafts.
Powered 4 Significance LLC was contracted by TEVA to provide medical writing assistance in preparing an initial draft of the manuscript and editorial assistance.
Competing Interests: The authors have read the journal’s policy and have the following competing interests: ADS, GB, and THC report research support from
GeminX, during the conduct of the study; HE reports compensation from Celgene, Novartis, Celator, Sunesis, Seattle Genetics, and Incyte, outside the submitted




Acute myeloid leukemia (AML) is a heterogeneous hematologic
malignancy that results from the clonal expansion of primitive
myeloid precursor cells [1]. AML is the most common form of
acute leukemia in adults, and has a high mortality. In the United
States, a total of 14,590 new AML diagnoses were projected to
occur in 2013, with an estimated 10,370 deaths [2]. AML is
predominantly a disease of older adults with a median age at
diagnosis of 66 years [3]. Compared with younger patients (,55
years), AML in older patients ($55 years) is more frequently
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associated with a poor prognosis, in part due to decreased response
rates and increased toxicity of standard induction chemotherapy.
Consequently, there is an unmet need for therapies that provide
efficacy and favorable tolerability in older patients with AML.
Development of small-molecule inhibitors specific for anti-
apoptotic proteins is a novel approach to the treatment of
hematologic cancers. Anti-apoptotic B cell-chronic lymphocytic
leukemia/lymphoma 2 (Bcl-2) family members (Bcl-2, Bcl-XL,
Bcl-w, Bcl-b, A1/Bfl-1, and Mcl-1) are overexpressed in many
cancers and inhibit apoptosis by sequestering pro-apoptotic
members of the family (BH3-only proteins, and Bax and Bak)
[4,5]. Importantly, emerging evidence suggests that anti-apoptotic
Mcl-1 is critical for sustained survival and expansion of human
AML and plays a role in drug resistance in this disease [6]. Since
interactions between anti- and pro-apoptotic family members are
mediated by the BH3 domain protein interaction motif [4,5],
small molecules that bind to the BH3 binding groove may induce
apoptosis by inhibiting sequestration of pro-apoptotic factors [7].
Obatoclax mesylate (obatoclax, also known as GX15-070) is a
novel anticancer therapeutic for hematologic malignancies and
solid tumors. The compound, which acts as a BH3 mimetic, was
developed as a pan-inhibitor of anti-apoptotic members of the Bcl-
2 family, including Mcl-1, to trigger cell death [8,9]. Preclinical
investigations demonstrated that obatoclax induces apoptosis and
reduces proliferation in AML cell lines and primary AML cells, in
part by inhibition of Mcl-1 sequestration of Bax [10].
In phase I trials of single-agent obatoclax, antitumor activity was
observed in several hematologic malignancies, including AML,
myelodysplastic syndrome, and Hodgkin’s and non-Hodgkin’s
lymphoma [11–14]. Although there were a limited number of
objective responses in these early clinical studies, hematologic
improvement was observed in a larger proportion of treated
patients. One striking clinical response occurred in a 70-year-old
woman with previously untreated AML who achieved a complete
response (CR) after receiving 20 mg/m2 obatoclax as a 24-hour
infusion [14]. Her CR was maintained over 8 months and
suggested that a subset of treatment-naive patients with AML
might benefit from obatoclax therapy.
Continuous infusion of obatoclax 60 mg/day for 3 days
(24 h63 d) in 2-week cycles has previously been evaluated in
phase II trials in patients with myelofibrosis or Hodgkin’s
lymphoma [13,15]. An accelerated 3-hour infusion, 3-day
(3 h63 d) regimen has not yet been evaluated in a 2-week cycle
in patients with hematologic malignancies, nor have these
regimens been formally compared. The objectives of this
multicenter phase I/II study were to expand on previous
experiences with obatoclax and to evaluate the dose and schedule
of single-agent obatoclax for safety and efficacy in older patients
with previously untreated AML.
Patients and Methods
Study Design
An open-label, multicenter, phase I/II study was conducted.
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. The phase I portion of the study consisted of a
nonrandomized safety evaluation, followed by a randomized phase
II evaluation of different treatment schedules (Figure 1). The
phase I safety evaluation assessed obatoclax as a 3-hour infusion
over 3 consecutive days (3 h63 d). Because the optimal schedule
for obatoclax treatment was unknown, the phase II evaluation
utilized a randomized open-label design to assess 3-hour or 24-
hour infusion schedules, over 3 consecutive days (3 h63 d or
24 h63 d). The selected dose for the 24-hour infusion was the
previously defined maximum tolerated dose (MTD) of 60 mg/day
[16].
Ethics Statement
The study was conducted in accordance with the October 2000
version of the Declaration of Helsinki, as well as Good Clinical
Practice and International Conference on Harmonisation guide-
lines. An accredited institutional review board approved this study
Figure 1. Study design. CR, complete response; DLT, dose-limiting toxicity.
doi:10.1371/journal.pone.0108694.g001
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prior to its initiation and all patients provided informed written
consent. This study was registered at clinicaltrials.gov
(NCT00684918).
Patient Eligibility
Patients at least 70 years of age with histologically confirmed
AML were eligible to participate. In the phase I portion of the
study, patients may have received one previous therapy. In the
phase II portion of the study, no prior therapy for AML was
allowed except for hydroxyurea. Additional eligibility require-
ments included Eastern Cooperative Oncology Group (ECOG)
performance status #2 and normal hepatic and renal function
(total bilirubin #2 mg/dL unless resulting from hemolysis;
aspartate transaminase/alanine transaminase #2.56 institutional
upper limit of normal; creatinine within normal institutional limits
or creatinine clearance $50 mL/min/1.73 m2 for patients with
creatinine levels above institutional normal).
Patients were excluded if they had a history of allergy to
components of the formulated product. Comorbidities requiring
patient exclusion included a history of seizure disorder or central
nervous system leukemia or other symptomatic neurologic illness;
uncontrolled systemic infection considered opportunistic, life-
threatening, or clinically significant; symptomatic congestive heart
failure; unstable angina pectoris; cardiac arrhythmia; significant
pulmonary disease or hypoxia; psychiatric illness/social situation
that would limit compliance with study requirements; or infection
with human immunodeficiency virus.
Treatments
Obatoclax mesylate (30 mg) was diluted with 5% dextrose, USP
and a final concentration of 11.54% polyethylene glycol 300,
0.46% polysorbate 20 for intravenous (IV) infusion. Treatments
were evaluated as depicted in Figure 1. In the phase I portion of
the study, the first 3 patients enrolled received obatoclax 30 mg/
day over 3 hours for 3 consecutive days (3 h63 d). Dose-limiting
toxicities (DLTs) were defined as grade $3 infusion-related
neurologic adverse events (AEs) and nonhematologic AEs not
responsive to symptom-directed therapy. If (during cycle 1) #1 of
the 3 patients experienced a DLT, subsequent enrolled patients
would receive 45 mg/day for 3 consecutive days (3 h63 d). If,
however, $2 of 3 patients experienced a DLT, an additional
group of 3 patients would be enrolled and would receive 20 mg/
day over 3 hours for 3 consecutive days (3 h63 d). If #1 of 3
patients experienced a DLT at 20 mg/day, this dose would be
utilized for the 3 h63 d phase II study. If $2 of the 3 patients
experienced a DLT at 20 mg/day, the 3 h63 d schedule would be
halted, and the phase II study would use only the 24 h63 d
schedule for obatoclax administration, which has previously been
shown to be well tolerated and produced a CR in a patient with
AML [14].
In the phase II portion of the study, patients were randomized
(1:1) into two arms. One arm received obatoclax at the dose
identified from phase I at 3 h63 d; the other arm received 60 mg/
day (24 h63 d). In both phases, obatoclax was administered in
two 2-week cycles as induction therapy. Any patient achieving a
CR could receive four additional treatment cycles as consolidation
therapy every 2 weeks for a total of six cycles of obatoclax
treatment. Patients who did not achieve CR after two cycles of
obatoclax were to be removed from study.
Prophylaxis with H-1 and H-2 blockers was recommended prior
to each cycle, given the known prevalence of acute hypersensitivity
reactions associated with obatoclax exposure [14]. Full supportive
care was offered to treat acute nausea, vomiting, or DLTs as
appropriate, including anti-emetic prophylaxis, blood products,
antibiotics, IV immunoglobulins, and hematopoietic growth
factors.
Endpoints and Assessments
Endpoints. Safety endpoints included number of DLTs,
treatment-emergent AEs, including serious AEs, and clinical
laboratory values. AEs were recorded according to the National
Cancer Institute Common Terminology Criteria for Adverse
Events, version 3.0 [17].
Clinical response was assessed using standard criteria [18]. The
primary efficacy endpoint was rate of morphologic CR, or
cytogenetic CR in patients with abnormal cytogenetics at baseline.
Morphologic CR was defined as neutrophils .1000/mL, platelets
.100,000/mL, and bone marrow blasts ,5%. Cytogenetic CR
was defined as neutrophils .1000/mL, platelets .100,000/mL,
bone marrow blasts ,5%, and normal cytogenetics. Additional
efficacy endpoints included molecular CR, partial remission (PR),
and morphologic leukemia-free state, and change in bone marrow
blasts from baseline to post-induction therapy (day 28).
Schedule of assessments. AEs were recorded from baseline
screening to 28 days after the last obatoclax dose. Complete blood
counts (absolute neutrophil count, lymphocytes, monocytes,
eosinophils, and basophils) were obtained on day 1 of each cycle,
every 2–3 days for the first week of cycle 1, and on day 8 of each
cycle. Physical and neurologic examinations, including vital signs,
body weight, ECOG performance status, and serum chemistries
were performed at baseline and on days 1 and 8 of each cycle.
Chest radiographs, pulmonary function tests, and urinalysis were
conducted at baseline and at the 28-day follow-up visit. An
electrocardiogram was obtained at baseline, 30 minutes before the
end of infusion on day 3 in cycle 1, and at the 28-day follow-up
visit, and repeated as clinically indicated.
Bone marrow aspirates and biopsies were conducted at baseline,
on day 28, after obatoclax consolidation therapy, and as clinically
indicated. CR was documented by repeat bone marrow exami-
nation on day 28 or earlier. Bone marrow cytogenetics were
assessed at baseline, repeated on occurrence of CR, and as
clinically indicated.
Statistical Analysis
Safety was assessed in all patients who received any amount of
study drug per National Cancer Institute Common Terminology
Criteria for Adverse Events, version 3. Efficacy was assessed in all
patients with at least one post-baseline efficacy assessment. All
outcomes were summarized descriptively. For categorical vari-
ables, summary tabulations of the number and percentage in each
parameter were provided. For continuous variables, the mean,
median, standard deviation, minimum, and maximum were
presented. To determine the rate of morphologic CR, a two-stage
design was used, powered to detect a CR rate of $15% against a
non-interesting rate of 5%, with alpha = 0.05 and a power of
90%. Stage 1 was to enroll 37 patients under this design, and if$3
patients achieved CR at the end of Stage 1, an additional 47
patients would be enrolled.
Results
Demographics and Patient Disposition
A total of 19 patients were enrolled in the study from March
2008 to March 2009; one patient did not receive obatoclax
treatment. Demographics and disease characteristics were similar
across all regimens (Table 1). Overall, the mean age was 81 years
(range 72–90 years). The median time from AML diagnosis to
study entry was 0.6 months (range 0–37 months). Most (56%)
Obatoclax in Older Patients with Untreated AML
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patients had a French-American-British classification of M2; the
distribution of AML classification was similar for all regimens.
Approximately 56% of patients had an abnormal karyotype;
further details of the cytogenetic abnormalities were not available,
thus precluding classification of cytogenetics into risk groups.
Patient disposition is shown in Figure 2. The most common
reasons for withdrawal from the study were failure to achieve CR
following induction therapy (eight patients, 42%), adverse events
(including DLT; four patients, 21%), and disease progression
(three patients, 16%). Two patients were granted waivers for
laboratory abnormalities (hyperuricemia) at baseline.
The number of treatment cycles administered in the phase I/II
studies is shown in Table 2. Overall, the median number of
cycles administered was two (range 1–11). In both the phase I and
II studies, a total of 15 patients (83%) were treated for at least two
cycles. Four patients also received additional treatment cycles as
consolidation therapy as they experienced disease stabilization or
decreased blast counts in the marrow, although these continued
cycles were considered protocol deviations. Of these four patients,
one patient received a total of eight cycles of therapy, two patients
received a total of four cycles, and one patient received a total of
11 cycles.
Safety
In the phase I safety study, two of three patients treated with
30 mg/day (3 h63 d) experienced grade 3 neurologic events that
led to discontinuation of treatment and were classified as DLTs
(Table 3). The first patient experienced grade 3 somnolence (day
1) and grade 3 confusion. This patient also experienced dizziness,
mood alteration, and speech disorder during infusion (all grade ,
3; Table 4). The second patient experienced grade 3 ataxia and
grade 1 confusion, euphoria, and somnolence on day 1 of cycle 1.
In both patients, neurologic DLTs were assessed as definitely
related to study drug and resolved within 24 hours. The third
patient in this group also experienced euphoria and ataxia (grade
,3) and discontinued due to leukemic infiltrate. One serious AE
(grade 3 neutropenic fever) was reported for this regimen, but was
judged to be unrelated to study drug (Table 3).
Per protocol, the obatoclax dose in the 3 h63 d regimen was
decreased to 20 mg/day in a subsequent cohort of three patients.
No additional DLTs were observed in this group and only one
grade 3 serious AE (pneumonia) was reported and was considered
unrelated to study drug. In addition, one patient experienced
grade 2 cytokine release syndrome, which was also considered a
serious AE (Table 3). Therefore, the 20 mg/day (3 h63 d)
regimen was chosen for the randomized phase II portion of the
Table 1. Demographics and baseline characteristics of obatoclax-treated patients (N = 18).
Phase I Phase II All (N=18)
30 mg/d (3 h63 d)
(n =3)
20 mg/d (3 h63 d)
(n =3)
20 mg/d (3 h63 d)
(n =7)
60 mg/d (24 h63 d)
(n=5)
Median (range) age, years 83 (81–85) 74 (72–90) 82 (72–89) 80 (76–86) 81.5 (72–90)
Male, n (%) 1 (33) 1 (33) 3 (43) 3 (60) 8 (44)
ECOG PS, n (%)
0 1 (33) 0 3 (43) 1 (20) 5 (28)
1 1 (33) 1 (33) 4 (57) 2 (40) 8 (44)
2 1 (33) 2 (67) 0 2 (40) 5 (28)
Median time since AML diagnosis,
months (range)
1 (0.5–7.4) 1.2 (1–16.7) 0.45 (20.2–0.6) 0.2 (0–37.2) 0.6 (20.2–37.2)
AML classification, n (%)
M1 1 (33) 0 3 (43) 0 4 (22)
M2 2 (67) 1 (33) 3 (43) 4 (80) 10 (56)
M3 0 1 (33)* 0 0 1 (6)
M4 0 1 (33) 0 1 (20) 2 (11)
Missing 0 0 1 (14) 0 1 (6)
Cytogenetics, n (%)
Abnormal 1 (33) 3 (100) 3 (43) 3 (60) 10 (56)
Normal 1 (33) 0 2 (29) 2 (40) 5 (28)
Missing 1 (33) 0 2 (29) 0 3 (17)
Median leukocyte count (range), 103/mL 1.3 (0.5–1.4) 29.2 (19.3–64.3) 4.3 (1.1–7.3) 2.8 (1.1–27.2) 4.25 (0.5–64.3)
Median platelet count (range), 103/mL 23 (8–154) 126 (69–227) 63 (19–518) 63 (19–259) 66 (8–518)
Median hemoglobin (range), g/L 86 (86–102) 105 (99–110) 101 (86–117) 93 (90–100) 97.5 (86–117)
Median neutrophil count (range), 103/mL 0.2 (0.2–0.2)a 1.95 (0.6–3.3)b 0.39 (0.1–2.6)c 6.98 (0.5–13.5)d 0.55 (0.1–13.5)e
*Classified as acute promyelocytic leukemia.
aEvaluated in 1 patient.
bEvaluated in 2 patients.
cEvaluated in 5 patients.
dEvaluated in 2 patients.
eEvaluated in 10 patients.
AML, acute myeloid leukemia; ECOG PS, Eastern Cooperative Oncology Group performance status.
doi:10.1371/journal.pone.0108694.t001
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study for comparison with obatoclax 60 mg/day (24 h63 d), as
previously defined in a small study of 18 patients [16].
In the phase II study, most patients receiving either obatoclax
20 mg/day (3 h63 d) or 60 mg/day (24 h63 d) experienced mild
to moderate (grade ,3), transient, neurologic AEs such as
euphoria, somnolence, ataxia, dizziness, and confusion (Table 4).
AEs of grade $3 that were reported in more than one patient
included febrile neutropenia (n = 3), dizziness (n = 2), atrial
fibrillation (n = 2), and acute myocardial infarction (n= 2). The
events of dizziness, atrial fibrillation, and acute myocardial
infarction were considered to be at least possibly related to
obatoclax. Acute myocardial infarction resulted in treatment
discontinuation in one patient.
Combining both the phase I and II components of the study, all
18 (100%) patients who received obatoclax experienced at least 1
AE, the most common of which were neurologic (n = 14; 77.8%)
or psychiatric (n = 16; 88.9%); most were transient and mild, and
resolved without sequelae. Ten patients experienced serious AEs;
details are provided in Table 3. Evidence for trends between
severity of AEs (grade $3) and dose or schedule was not observed
(Table 4). AEs (any grade) with the highest reported incidence
included euphoria (67%), somnolence (44%), and ataxia (39%).
Figure 2. Patient disposition. AE, adverse event; CR, complete response.
doi:10.1371/journal.pone.0108694.g002
Table 2. Study drug exposure in patients treated with obatoclax (N = 18).
Phase I Phase II All (N=18)
30 mg/d (n=3) 20 mg/d (n =3)
3-h infusion (20 mg/d)
(n =7)
24-h infusion (60 mg/d)
(n=5)
Median number of cycles (range) 2 (1–2) 4 (4–8) 2 (2–11) 2 (1–2) 2 (1–11)
Total cycles, n (%)
1 3 (100) 3 (100) 7 (100) 5 (100) 18 (100)
2 2 (67) 3 (100) 7 (100) 3 (60) 15 (83)
3 0 3 (100) 1 (14) 0 4 (22)
4 0 3 (100) 1 (14) 0 4 (22)
5 0 1 (33) 1 (14) 0 2 (11)
6 0 1 (33) 1 (14) 0 2 (11)
7 0 1 (33) 1 (14) 0 2 (11)
8 0 1 (33) 1 (14) 0 2 (11)
.9 0 0 1 (14) 0 1 (6)
doi:10.1371/journal.pone.0108694.t002
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Somnolence was the most commonly reported grade $3 AE
(17%). The most common grade $3 toxicities based on laboratory
data were leukocytosis and thrombocytopenia (each n=9). No
clinically meaningful differences were observed across regimens for
laboratory reports of grade $3 hematologic findings.
Two patients died during the study for reasons unrelated to
obatoclax administration. One patient on the 60 mg/day
(24 h63 d) regimen died on day 23 of the study from progressive
disease. The second patient, receiving 20 mg/day (3 h63 d), died
on day 41; the cause of death is unknown. An additional six
patients died more than 30 days after the last obatoclax dose.
Causes of death in these patients were progressive disease (n = 2),
sepsis (n = 1), and unknown (n = 3).
Efficacy
CR was not achieved with obatoclax induction. However, three
patients on the 20 mg/day (3 h63 d) regimen demonstrated a 7%
to 17% decrease in bone marrow blast percentage between the
baseline assessment and the end of cycle 2 (Table 5). It is
noteworthy that two of these patients with decreased marrow
blasts also demonstrated an increase of 33% to 57% in neutrophil
count. Of these three patients, one patient in phase I receiving
obatoclax 20 mg/day (3 h63 d arm) had a decrease in marrow
blasts from 27% to 10% with increased neutrophils from
93446103/mL to 14,7006103/mL. This patient received eight
cycles of study treatment and withdrew from the study on the
advice of the investigator. One additional patient in the phase II
portion of the study had increased neutrophil (pre-treatment:
2306103/mL; end of cycle 2: 25006103/mL) and platelet counts
(pre-treatment: 736103/mL; end of cycle 2: 2506103/mL) without
a significant change in the marrow blasts. This patient remained
stable and received 11 cycles of obatoclax.
Discussion
The results of the current study demonstrate that the safety
profile of obatoclax administered for 3 consecutive days (every 2
weeks) by 3-hour or 24-hour infusion was generally mild and
similar to previous reports [11–14]. AEs were typically transient,
neurologic, or psychiatric findings that resolved without sequelae.
Based on the safety profile, 20 mg/day was determined to be the
MTD of obatoclax when administered over 3 hours/day for 3
consecutive days in older AML patients. Two patients treated with
the 30 mg/day (3 h63 d) regimen experienced DLTs consisting of
grade 3 confusion, somnolence, or ataxia, which led to premature
discontinuation and selection of the 20 mg/day dose for further
evaluation. In the phase II comparison of obatoclax 20 mg/day
(3 h63 d) to the previously evaluated 60 mg/day (24 h63 d)
regimen, both dosing schedules demonstrated similar safety
profiles.
The mechanism(s) underlying the development of neurologic or
psychiatric symptoms is uncertain. However, it is plausible that
these symptoms represent an on-target effect, since Bcl-2 promotes
neuron survival and Bcl-XL plays a role in synaptic plasticity
[19,20]. Alternatively, the neurologic and psychiatric effects of
obatoclax may reflect binding to targets other than Bcl-2 family
members.
Based on laboratory data, grade $3 leukocytosis and throm-
bocytopenia occurred in 50% of patients in this study. These
hematologic abnormalities are likely related to underlying disease
rather than obatoclax as they were present at baseline. However, it
should be noted that inhibition of Bcl-XL by obatoclax may result
in thrombocytopenia. Because patients also received platelet
transfusions during the study as supportive care, the impact of
obatoclax on platelet production may have been obscured.
Six patients experienced cardiac events during this study, four of
which were assessed as at least possibly related to the study drug.
The causal relationship with ischemic cardiac events, if any, is
unclear because patients in this study were older with multiple
comorbidities. In other clinical studies evaluating obatoclax, QTc
prolongation has been reported by automated electrocardiogram.
In a study of patients with relapsed small cell lung cancer, the
interval between obatoclax doses was extended to 3 days in a
Table 3. Summary of dose-limiting toxicities and serious adverse events.
Phase I Phase II
30 mg/d (n=3) 20 mg/d (n =3)
3-h infusion (20 mg/d)
(n =7)
24-h infusion (60 mg/d)
(n =5)
Dose-limiting toxicity Grade 3 somnolence/confusion
(1); grade 3 ataxia (1)
0 0 0
Serious TEAE, n (grade,
attribution)
Febrile neutropenia 1 (gr 3, NR) 1 (gr 3, NR)
Atrial fibrillation 2 (gr 3, NR; gr 3, NR)
Acute myocardial infarction 1 (gr 3, NR) 1 (gr 4, PS)
Cough 2 (gr 1, NR; gr 2, PS)
Catheter site infection 1 (gr 3, NR) 1 (gr 3, NR)
Cytokine release syndrome 1 (gr 2, PR)
Pneumonia 1 (gr 3, NR) 1 (gr 3, NR)
Acute sinusitis 1 (gr 1, NR)
Dyspnea 1 (gr 2, NR)
Fatigue 1 (gr 5, NR)
Dizziness 1 (gr 3, PR)
AE, adverse event; DLT, dose-limiting toxicity (DLTs were defined as grade $3 infusion-related neurologic AEs and nonhematologic AEs not responsive to symptom-
directed therapy); PR, probably related; PS, possibly related; NR, not related; TEAE, treatment-emergent adverse event.
doi:10.1371/journal.pone.0108694.t003
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single patient who experienced QTc prolongation during the first
cycle [14,21]. In another phase I dose escalation study in advanced
hematologic malignancies, grade 3 QTc prolongation was
observed in 3 patients, but was confounded by the presence of
QTc prolongation at baseline [14]. Notably, an imbalance in the
ratio of anti-apoptotic to pro-apoptotic Bcl-2 proteins appears
causal in the development of cardiovascular disease, including
ischemic heart disease [22], so relationship to study drug cannot be
excluded.
In the current study, four patients had a clinical response of
stable disease and were treated for up to 11 cycles. We did not
observe a CR in this study. This contrasts with our previous report
of a CR achieved with single-agent obatoclax (20 mg/m2 over
24 hours) in one older treatment-naive patient with AML with a
mixed-lineage leukemia (MLL) t(9;11) translocation [14]. Al-
though such dramatic single-agent activity in previously untreated
AML was not confirmed by our data, it is possible that MLL-
associated leukemia may be particularly sensitive to Bcl-2 family
inhibitors. Preclinical studies have shown that inhibition of MLL
expression using siRNA corresponded with reduced Bcl-XL levels
and leukemic proliferation that may be mediated by HoxA9
[23,24]. Thus, Bcl-2 proteins may play an important role in the
proliferation of MLL-associated leukemia. In addition, a limitation
of our study is that pharmacodynamic activity or pharmacokinetic
parameters were not assessed. Integrating these evaluations in
future clinical trials of obatoclax may provide further insight into
the clinical potential of obatoclax as a single agent.
In addition to obatoclax, several other small-molecule BH3
mimetics are under investigation. ABT-737 and ABT-263
(navitoclax), for example, bind three of six Bcl-2 family members
with high affinity [25,26]. Navitoclax has been evaluated in phase
I trials in lymphoid malignancies [27,28]. However, these
inhibitors do not bind Mcl-1 with as high affinity, and their
therapeutic potential is constrained by dose-limiting thrombocy-
topenia associated with potent Bcl-XL inhibition in platelets [29].
Obatoclax was developed as a promiscuous Bcl-2 family inhibitor
and also inhibits Mcl-1, which is essential for development and
sustained growth of AML [6]. Follow-on analysis of the correlation
between anti-apoptotic Bcl-2 proteins and obatoclax response was
not conducted in this study, and will be important to include in
future phase II evaluations.
It is conceivable, given their mechanism of action, that Bcl-2
family inhibitors might be most active in combination with other
inducers of cell death. For example, obatoclax induced apoptosis
in OCI-AML3 leukemic cells when used in combination with
ABT-737 and synergistically induced apoptosis in combination
with cytosine arabinoside in leukemic cell lines and in primary
AML samples [10]. Preclinical investigations also suggest that
obatoclax potentiates the effect of established drugs in AML [30–
32], and several clinical trials of obatoclax combined with
conventional chemotherapeutic agents have been completed or
are ongoing in a range of solid tumors and hematologic
malignancies (e.g., NCT00612612, NCT00521144 at clinical-
trials.gov).
In conclusion, based on the safety profile described in this study,
20 mg/day is the MTD of obatoclax when administered by 3-hour
infusion over 3 consecutive days in an older AML population, and
it has similar tolerability to a 60 mg/day (24 h63 d) regimen.
Although the current study does not support the efficacy of
obatoclax as a single agent in an unselected group of treatment-
naive AML patients, additional studies may reveal activity in select
subgroups, particularly in combination with other chemothera-
peutics.
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